CRISPR-Cas9 as a Targeted Therapeutic Strategy for Primary Hyperoxaluria: A New Frontier in Gene-Based Nephrology
DOI:
https://doi.org/10.63501/ephy8993Keywords:
CRISPR, Gene editing, primary hyperoxaluriaAbstract
Primary hyperoxaluria (PH), most commonly caused by mutations in the AGXT gene (type 1), is a rare inherited metabolic disorder leading to oxalate overproduction and progressive renal damage. Current treatments, including pyridoxine supplementation and RNA interference therapies, are supportive but not curative, with liver–kidney transplantation remaining the definitive option. CRISPR-Cas9 gene-editing technology offers a potential one-time curative solution by directly correcting pathogenic mutations or silencing disease-related genes. Recent preclinical studies and early clinical trials, such as those investigating YOLT-203, have shown promising reductions in urinary oxalate with minimal toxicity. However, challenges related to long-term safety, delivery, cost, and ethical concerns must be addressed. With further research and responsible innovation, CRISPR-Cas9 could revolutionize the treatment landscape of primary hyperoxaluria.
References
Garrelfs, S. F., Frishberg, Y., Hulton, S. A., Koren, M. J., O’Riordan, W. D., Cochat, P., Deschênes, G., Shasha-Lavsky, H., Saland, J. M., van’t Hoff, W. G., Fuster, D. G., Magen, D., Moochhala, S. H., Schalk, G., Simkova, E., Groothoff, J. W., Sas, D. J., Meliambro, K. A., Lu, J., … Lieske, J. C. (2021). Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. New England Journal of Medicine, 384(13), 1216–1226. https://doi.org/10.1056/nejmoa2021712
Doudna, J. A. (2020). The promise and challenge of therapeutic genome editing. In Nature (Vol. 578, Issue 7794, pp. 229–236). Nature Research. https://doi.org/10.1038/s41586-020-1978-5
Jiang, Y., Chen, S., Hsiao, S., Zhang, H., Xie, D., Wang, Z. J., Ren, W., Liu, M., Liao, J., & Wu, Y. (2025). Efficient and safe in vivo treatment of primary hyperoxaluria type 1 via LNP-CRISPR-Cas9-mediated glycolate oxidase disruption. Molecular Therapy, 33(1), 104–118. https://doi.org/10.1016/j.ymthe.2024.10.003
YolTech Therapeutics. (2025, February 25). YolTech Therapeutics Announces Positive Clinical Data for YOLT-203, an In Vivo Gene Editing Therapy for Primary Hyperoxaluria Type 1 (PH1). YolTech Therapeutics. https://www.yoltx.com/news/press-release/74
ClinicalTrials.gov. (2024, December 19). Clinical exploration study of YOLT-203 in the treatment of type 1 primary hyperoxaluria (PH1). ClinicalTrials.Gov. https://clinicaltrials.gov/study/NCT06511349
ClinicalTrials.gov. (2024, December 19). Clinical exploration study of YOLT-203 in the treatment of type 1 primary hyperoxaluria (PH1). ClinicalTrials.Gov. https://clinicaltrials.gov/study/NCT06511349
YolTech Therapeutics. (2024, August 22). YolTech Therapeutics administers first patient dose in IIT of YOLT-203, the world’s first in vivo gene editing therapy for PH1. YolTech Therapeutics. https://www.yoltx.com/news/press-release/67